Acuitas Investments LLC Lowers Position in XOMA Royalty Corporation (NASDAQ:XOMA)

Acuitas Investments LLC lowered its stake in shares of XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) by 90.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,674 shares of the biotechnology company's stock after selling 55,030 shares during the quarter. Acuitas Investments LLC's holdings in XOMA Royalty were worth $113,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of XOMA. GAMMA Investing LLC raised its position in XOMA Royalty by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,585 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of XOMA Royalty by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after buying an additional 800 shares during the period. Wells Fargo & Company MN raised its holdings in XOMA Royalty by 38.0% in the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after acquiring an additional 1,183 shares in the last quarter. Bank of America Corp DE lifted its stake in XOMA Royalty by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock worth $205,000 after acquiring an additional 2,009 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in XOMA Royalty during the 4th quarter worth approximately $206,000. 95.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes sold 25,637 shares of the firm's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total transaction of $650,667.06. Following the transaction, the chief executive officer directly owned 62,701 shares of the company's stock, valued at approximately $1,591,351.38. This trade represents a 29.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Joseph M. Limber purchased 5,243 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $25.60 per share, for a total transaction of $134,220.80. Following the acquisition, the director owned 10,000 shares of the company's stock, valued at approximately $256,000. The trade was a 110.22% increase in their ownership of the stock. The disclosure for this purchase can be found here. 9.10% of the stock is currently owned by company insiders.

XOMA Royalty Stock Performance

NASDAQ XOMA traded up $0.32 during trading hours on Friday, hitting $26.43. The company had a trading volume of 25,289 shares, compared to its average volume of 35,139. The business has a 50 day moving average of $25.28 and a 200-day moving average of $24.23. The company has a market cap of $316.41 million, a PE ratio of -22.99 and a beta of 0.93. XOMA Royalty Corporation has a 1-year low of $18.35 and a 1-year high of $35.00. The company has a debt-to-equity ratio of 1.18, a quick ratio of 5.54 and a current ratio of 5.54.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.32. The business had revenue of $15.91 million during the quarter, compared to the consensus estimate of $6.75 million. XOMA Royalty had a negative return on equity of 12.43% and a negative net margin of 13.04%. As a group, equities research analysts expect that XOMA Royalty Corporation will post -1.41 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Benchmark assumed coverage on shares of XOMA Royalty in a report on Thursday, April 17th. They issued a "buy" rating and a $35.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $104.00 price target on shares of XOMA Royalty in a research note on Wednesday, May 28th. Finally, Wall Street Zen cut XOMA Royalty from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.